Bunker Hill.png
Bunker Hill Launches Extensive Ground Geophysics Program
June 16, 2021 07:00 ET | Bunker Hill Mining Corp.
Sam Ash, CEO and David Wiens, CFO to host Live Interactive Virtual Investor Event on Wednesday, June 16 @ 11:00am ET / 8:00am PT. Investors are invited to register for this event at: LINK TORONTO,...
altimmune-logo.png
Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers
June 16, 2021 07:00 ET | Altimmune, Inc.
Weight loss of 5.4% achieved at 6 weeks of treatment with 1.8 mg once weekly dose, surpassing the 2% pre-established treatment targetAscending multi-dose regimen well-tolerated without necessity for...
Tonix2.jpg
Tonix Pharmaceuticals to Present at Raymond James Human Health Innovation Conference
June 16, 2021 07:00 ET | Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 16, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth...
Annexon_Logo_RGB.png
Annexon to Present at the Raymond James Human Health Innovation Conference
June 16, 2021 07:00 ET | Annexon Biosciences
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Appoints Laura L. Parks, Ph.D. to Board of Directors
June 16, 2021 07:00 ET | Recro Pharma, Inc.
EXTON, Pa., June 16, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Freeline_Logo_Red_RGB.jpg
Freeline Doses Second Patient of Phase 1/2 MARVEL-1 Clinical Trial for Fabry Disease
June 16, 2021 07:00 ET | Freeline Therapeutics
Lowest dose cohort complete and study positioned for dose escalation Company to present FLT190 data by year-end LONDON, June 16, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc...
TrevenaLogo.jpg
Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder
June 16, 2021 07:00 ET | Trevena Inc.
-- TRV734 reduced drug-seeking behavior in a preclinical model of relapse, suggesting its utility as a novel oral maintenance treatment for opioid use disorder The study is being conducted and...
BioCryst.jpg
BioCryst Announces Acceptance and Accelerated Review of the ORLADEYO™ (berotralstat) Marketing Application by the Israeli Ministry of Health
June 16, 2021 07:00 ET | BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry of Health has accepted the regulatory...
REPORT: Wanting a re
REPORT: Wanting a return to “normal”, many struggling Indigenous businesses are showing strength, resilience, and adaptability despite continued barriers
June 16, 2021 07:00 ET | Canadian Council for Aboriginal Business
Toronto, June 16, 2021 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE   New report: Wanting a return to “normal”, many struggling Indigenous businesses are showing strength, resilience, and...
CW Only RGB.jpg.jpeg
CW Petroleum Corp (CWPE): 2021 Sales on Track to Exceed 2020 for 6-Months Ending 6/30/2021, Identifies Capital Funding Group.
June 16, 2021 07:00 ET | CW Petroleum Corp
Katy, Texas, June 16, 2021 (GLOBE NEWSWIRE) -- CW Petroleum Corp (OTCQB: CWPE), a leading provider of Proprietary Reformulated No Ethanol Gasoline and Biofuels, announce today forecasted Revenue for...